Homglobin Electrophoresis
Diagnostic TestTo diagnose thalassaemia &best method to control disease progress
NCT Number: NCT06720480
This study aims to develop a nuanced understanding of thalassemia severity in Upper Egypt by integrating various clinical parameters beyond transfusion frequency. By doing so, it seeks to enhance patient management and ultimately improve quality of life for those affected by this condition.
Trial opening soon.
Get Notified6 month–18 year
All sexes
Observational
Thalassemia syndrome classified as hemoglobinopathies, represent one of the most prevalent classes of single-gene disorders globally. The mutations in the HBB gene lead to variable impacts on the production of globin proteins, which in turn affects the overall function of hemoglobin. The genetic variants contribute significantly to the diverse clinical presentations and severity of thalassemia. Traditionally, thalassemia has been categorized into Major, intermediate, and Minor based on the frequency of blood transfusions required for survival It has been observed that anemia may not be the sole determinant of thalassemic disease severity, other factors are also responsible for overall clinical status.
Accordingly, clinical conditions of the thalassemia patient, cannot classified based on the transfusion status.
Phadke et al. (2006), proposed a classification that considers multiple parameters beyond transfusion status . Similarly, Sripichai et al , (2008) classified HbE/β-thalassemia into the 3 categories of mild, moderate, and severe. Another classification was also introduced by Thalassemia International Federation (TIF) , which 'was bit modification Sripichai et al 2008 . Despite these advancements, existing classifications still tend to simplify thalassemia into three categories Globally, An estimated 1-5% of the global population are carriers of a genetic thalassemia mutation.Although the epidemiology of the various clinical forms remains poorly recognized, the disease is known to be highly prevalent in the area extending from sub-Saharan Africa, through the Mediterranean region and Middle East, to the Indian subcontinent and East and Southeast Asia.Thus, >90% of patients with these disorders live in low- and middle-income countries
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To diagnose thalassaemia &best method to control disease progress
Time frame: 1year
Contact information is provided by the study sponsor or research team.
AlZhraa Gaber Mohamed, Master degree
CONTACT
800-555-5555 ext. 01091888986
Khalid Ibrahim Abdrahman El-sayeh, Proffesour
CONTACT
Assiut University
Other
Thalassaemia Severity Score in Upper Egypt Patients Attending Assuit University Children Hospital
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07206095
Anemia, Anemia Due to Membrane Defect
Barcelona, Spain
View Trial DetailsNCT07698080
Anemia, Anemia, Aplastic
View Trial DetailsNCT07673302
Anemia, Anemia, Hemolytic
Rawalpindi, Punjab Province, Pakistan
View Trial DetailsNCT07660224
Anemia, Anemia, Hemolytic
View Trial Details